It is a potentially deadly health condition that plagues more than half of all British adults. High cholesterol causes a sticky form of fat to build up in the arteries, blocking blood flow. Left ...
Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...
Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories agreed to acquire cancer-screening ...
North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...
Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...
Abbott's acquisition of Exact Sciences aims to improve cancer diagnostics and expand access to early detection and management. Exact Sciences' products, including Cologuard and Oncotype DX, will ...
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics ...
News of an apparently impending sale to a strategic investor sent shares of Exact Sciences (NASDAQ: EXAS) skyward on Wednesday. The cancer diagnostics specialist's shares closed the day nearly 24% ...
The rumors are now a reality. Abbott Laboratories is acquiring Exact Sciences for $21 billion, marking what could be the biggest medtech deal of 2025. The deal’s announcement comes less than 24 hours ...
Bloomberg reports today that Abbott (NYSE: ABT) + is close to a deal to acquire diagnostics developer Exact Sciences (Nasdaq:EXAS). The report cites people familiar with the matter. They reportedly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback